Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Annexon (Nasdaq: ANNX) reported Q1 2026 results and portfolio progress, with key near-term clinical and regulatory milestones. Topline Phase 3 ARCHER II data for vonaprument in geographic atrophy is expected in Q4 2026. Tanruprubart MAA is under EMA review and a BLA submission with FORWARD data is anticipated in 2026. ANX1502 proof-of-concept data is expected in 2026. Cash, cash equivalents and short-term investments totaled $225.0 million as of March 31, 2026, with runway into the second half of 2027.
Annexon (Nasdaq: ANNX) will present at the Bank of America Securities Health Care Conference on May 13, 2026 at 11:20 a.m. PT. Douglas Love, President and CEO, will deliver the presentation.
A live webcast is available via the company Investors page and a replay will be archived for 30 days.
Annexon (Nasdaq: ANNX) announced that CEO Douglas Love will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET.
A live webcast will be available on the company's Investors "Events & Presentations" page and a replay will be archived on the Annexon website for 30 days after the presentation.
Annexon (NASDAQ: ANNX) reported fourth-quarter and full-year 2025 results, highlighted portfolio progress, and outlined 2026 milestones. Key updates: ARCHER II topline Phase 3 data expected Q4 2026, tanruprubart MAA filed in EU with a planned U.S. BLA submission in 2026, and ANX1502 POC data anticipated in 2026.
Financials: $238.3 million cash and short-term investments at 12/31/2025 (runway into H2 2027); 2025 net loss $208.5 million; 2025 R&D expense $184.7 million.
Annexon (Nasdaq: ANNX) granted an inducement option to a new non-executive employee under its 2022 Employment Inducement Award Plan.
The board approved the award on March 12, 2026; the option to buy 20,000 shares was granted at a $5.66 exercise price on March 13, 2026, carries a ten-year term and vests over four years (25% at year one, then monthly 1/48th).
Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.
A live webcast will be available via the company’s Investors "Events & Presentations" page and a replay will be archived for 30 days following the presentation.
Annexon (Nasdaq: ANNX) will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET.
Expert retina specialists will review dry age-related macular degeneration with geographic atrophy, the role of C1q, Annexon’s neuroprotective C1q inhibitor vonaprument, and the pivotal Phase 3 ARCHER II trial, with topline data expected in the second half of 2026.
Annexon (Nasdaq: ANNX) announced inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on January 9, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the hires received options to purchase 155,000 shares of common stock. The options have a 10-year term, an exercise price of $6.16 per share (the closing price on January 15, 2026, the grant date), and vest over 4 years with 25% vesting at the first anniversary and the remainder vesting monthly thereafter, subject to continued service.
Annexon (NASDAQ: ANNX) outlined 2026 priorities and registrational milestones for its targeted immunotherapy platform. Key updates: MAA filed for tanruprubart in Europe with a planned U.S. BLA submission in 2026 supported by the FORWARD study; vonaprument Phase 3 ARCHER II enrollment completed (659 patients) with topline data expected in H2 2026; ANX1502 proof-of-concept readout in cold agglutinin disease expected in 2026. Company states a strong cash position funding operations into late 2027 and plans a GA Investor Day in March 2026.
Annexon (Nasdaq: ANNX) submitted a Marketing Authorization Application (MAA) to the European Medicines Agency on Jan 8, 2026 for tanruprubart to treat Guillain-Barré syndrome (GBS).
The dossier includes randomized placebo-controlled proof-of-concept and pivotal Phase 3 data showing rapid reduction of neuroinflammation after a single infusion, measurement of improved functional and disability outcomes, a large U.S. and Southeast Asian biomarker dataset, population PK across regions, and a real-world evidence comparison to IVIg/plasma exchange. Tanruprubart has European and FDA Orphan Drug designations. An FDA BLA submission using FORWARD study data is planned in 2026.